Medtronic (NYSE:MDT) EVP Harry Skip Kiil Sells 52,524 Shares of Stock

Medtronic PLC (NYSE:MDT) EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Medtronic Trading Up 0.3%

Shares of Medtronic stock opened at $96.97 on Friday. The stock has a market capitalization of $124.50 billion, a P/E ratio of 27.01, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.54. The stock’s 50-day simple moving average is $98.95 and its 200 day simple moving average is $96.83. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the company earned $1.38 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s dividend payout ratio is currently 79.11%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. UBS Group restated a “neutral” rating and set a $104.00 price objective on shares of Medtronic in a report on Wednesday, February 4th. Citigroup initiated coverage on Medtronic in a report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 target price for the company. Mizuho upgraded shares of Medtronic to a “strong-buy” rating in a research note on Wednesday, February 18th. Finally, Daiwa Securities Group lifted their price target on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.84.

Hedge Funds Weigh In On Medtronic

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Monetary Solutions Ltd bought a new stake in Medtronic during the fourth quarter worth approximately $27,000. Corundum Trust Company INC bought a new stake in shares of Medtronic during the 3rd quarter worth $27,000. Lodestone Wealth Management LLC acquired a new stake in Medtronic in the 4th quarter valued at approximately $27,000. Anfield Capital Management LLC raised its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares during the last quarter. Finally, Board of the Pension Protection Fund bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).